Identification of multiple glutathione conjugates of 8-amino-2-methyl-4- phenyl-1,2,3,4-tetrahydroisoquinoline maleate (nomifensine) in liver microsomes and hepatocyte preparations: Evidence of the bioactivation of nomifensine

Drug Metabolism and Disposition

Volumn 38, Issue 1, 2010, Pages 46-60

  Yu, Jian ^a   Mathisen, Donald E ^a   Burdette, Doug ^a   Brown, Dean G ^a   Becker, Christopher ^a   Aharony, David ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANILINE; GLUTATHIONE; GLUTATHIONE DERIVATIVE; GLUTATHIONE SULFINAMIDE; NOMIFENSINE; NOMIFENSINE DIHYDROISOQUINOLINIUM PERCHLORATE; PERCHLORATE; POLYCYCLIC AROMATIC HYDROCARBON; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONJUGATE; CONJUGATION; CONTROLLED STUDY; DOG; DRUG ACTIVITY; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; LIVER CELL; LIVER MICROSOME; MONKEY; NONHUMAN; OXIDATION; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY;

ANIMALS; BIOTRANSFORMATION; CHROMATOGRAPHY, LIQUID; DOGS; FOURIER ANALYSIS; GLUTATHIONE; HEPATOCYTES; HUMANS; MACACA FASCICULARIS; MICROSOMES, LIVER; MODELS, CHEMICAL; MOLECULAR STRUCTURE; MOLECULAR WEIGHT; NADP; NOMIFENSINE; RATS; RATS, SPRAGUE-DAWLEY; TANDEM MASS SPECTROMETRY;

ANIMALIA; CANIS FAMILIARIS; RATTUS;

EID: 73149103473     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.028803     Document Type: Article

References (28)

1. Baillie TA and Davis MR (1993) Mass spectrometry in the analysis of glutathione conjugates. Biol Mass Spectrom 22:319-325.
2. Baldessarini RJ (1982) Overview of recent advantages in antidepressant pharmacology: part II. Mclean Hosp J 7:1-27.
3. Ballard KD, Raftery MJ, Jaeschke H, and Gaskell SJ (1991) Multiple scan modes in the hybrid tandem mass spectrometric screening and characterization of the glutathione conjugate of 2-furamide. J Am Soc Mass Spectrom 2:55-68.
4. Brogden RN, Heel RC, Speight TM, and Avery GS (1979) Nomifensine: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs 18:1-24.
5. Calam DH and Waley SG (1962) Some derivatives of glutathione. Biochem J 85:417-419.
6. Fielding S and Szewczak MR (1984) Pharmacology of nomifensine: a review of animal studies. J Clin Psychiatry 45:12-20.
7. Heptner W, Hornke I, Cavagna F, Fehlhaber HW, Rupp W, and Neubauer HP (1978) Metabolism of nomifensine in man and animal species. Arzneimittelforschung 28:58-64.
8. Hoffmann I (1977) A comparative review of the pharmacology of nomifensine. Br J Clin Pharmacol 4:69S-75S.
9. Hoffman I (1982) Pharmacology of nomifensine. Int Pharmacopsychiatry 17(Suppl 1):4-20.
10. Hornke I, Fehlhaber HW, Girg M, and Jantz H (1980) Metabolism of nomifensine (Alival, Merital): isolation and identification of the conjugates of nomifensine-14C from human urine. Br J Clin Pharmacol 9:255-264.
11. Kalgutkar AS, Gardner I, Obach RS, Shaffer CL, Callegari E, Henne KR, Mutlib AE, Dalvie DK, Lee JS, Nakai Y, et al. (2005) A comprehensive listing of bioactivation pathways of organic functional groups. Curr Drug Metab 6:161-225.
12. Kalgutkar AS and Soglia JR (2005) Minimising the potential for metabolic activation in drug discovery. Expert Opin Drug Metab Toxicol 1:91-142.
13. Kellner HM, Baeder C, Christ O, Heptner W, Hornke I, and Ings RM (1977) Kinetics and metabolism of nomifensine in animals. Br J Clin Pharmacol 4(Suppl 2):109S-116S.
14. Kinney JL (1985) Nomifensine maleate: a new second-generation antidepressant. Clin Pharm 4:625-636.
15. Kostowski W, Valzelli L, Kozak W, and Bernasconi S (1984) Activity of desipramine, fluoxetine and nomifensine on spontaneous and p-CPA-induced muricidal aggression. Pharmacol Res Commun 16:265-271.
16. Kummer H, Marti F, and Wegmann W (1985) Granulomatous hepatitis caused by nomifensine. Schweiz Med Wochenschr 115:1674-1678.
17. Lessard E, Hamelin BA, Labbé L, O'Hara G, Bélanger PM, and Turgeon J (1999) Involvement of CYP2D6 activity in the N-oxidation of procainamide in man. Pharmacogenetics 9:683-696.
18. Lindberg RL and Syvälahti EK (1986) Metabolism of nomifensine after oral and intravenous administration. Clin Pharmacol Ther 39:378-383.
19. Moehrle H and Biegholdt M (1988) Carbinolamine equivalents in the 8-aminotetrahydroisoquinoline series. Arch Pharm (Weinbeim) 321:287-291.
20. Nielsen JL and Lund NO (1981) Drug fever due to nomifensine treatment in patients with endogenous depression. Int Pharmacopsychiatry 16:66-68.
21. Obach RS and Dalvie DK (2006) Metabolism of nomifensine to a dihydroisoquinolinium ion metabolite by human myeloperoxidase, hemoglobin, monoamine oxidase A, and cytochrome P450 enzymes. Drug Metab Dispos 34:1310-1316.
22. Parkinson A (2001) Biotransformation of xenobiotics, in Casarett and Doull's Toxicology: The Basic Science of Poisons, 6th ed. (Klaassen CD ed), pp 133-224, McGraw-Hill, New York.
23. Salama A and Mueller-Eckhardt C (1985) The role of metabolite-specific antibodies in nomifensine-dependent immune hemolytic anemia. N Engl J Med 313:469-474.
24. Salama A and Mueller-Eckhardt C (1986) Two types of nomifensine-induced immune haemolytic anaemias: drug-dependent sensitization and/or autoimmunization. Br J Haematol 64: 613-620.
25. Salama A, Santoso S, and Mueller-Eckhardt C (1991) Antigenic determinants responsible for the reactions of drug-dependent antibodies with blood cells. Br J Haematol 78:535-539.
26. Stonier PD and Edwards JG (2002) Nomifensine and haemolytic anemia, in Pharmacovigilance (Mann RD and Andrews EB eds) pp 155-166, Wiley, New York.
27. Uetrecht JP (1985) Reactivity and possible significance of hydroxylamine and nitroso metabolites of procainamide. J Pharmacol Exp Ther 232:420-425.
28. Venkov A and Vodenicharov D (1990) A new synthesis of 1,2,3,4-tetrahydro-2-methyl-4-phenylisoquinolines. Synthesis 253-255.